FDA Authorizes Aletta, the First Standalone Robotic Blood Draw Device, via De Novo Pathway (August 19, 2026)

At a Glance

• On August 19, 2026, the U.S. FDA authorized Vitestro's Aletta robotic blood draw device for marketing.
• Aletta is the first standalone robotic device that draws blood from a patient's arm without manual operator intervention.
• The device is indicated for adult outpatient settings and must be operated under the supervision of a phlebotomy-trained supervisor; one phlebotomist may oversee up to three Aletta devices simultaneously.
• The authorization was granted through the De Novo pathway, and FDA is establishing special controls covering labeling, performance testing and clinical testing.
• Companies developing blood collection devices and related in vitro diagnostic accessories for the U.S. market should review product classification, clinical evaluation and quality system compliance requirements.

Full Text: FDA Authorizes First-of-its-Kind Robotic Blood Draw Device

For Immediate Release: August 19, 2026

The U.S. Food and Drug Administration today authorized the marketing of Aletta, the first standalone robotic device that draws blood from a patient's arm without manual operator intervention. The device is authorized for use in adult outpatient settings and must be operated under the supervision of a supervisor trained in phlebotomy. A single phlebotomist may supervise up to three Aletta devices at the same time, which may help alleviate the current shortage of phlebotomists in the United States.

“Today's authorization reflects the FDA's commitment to advancing innovative medical devices that help meet critical public health needs while maintaining the safety and effectiveness patients deserve,” said Michelle Tarver, M.D., Ph.D., director of the FDA's Center for Devices and Radiological Health. “Blood draws are one of the most commonly performed medical procedures in the United States, yet patients may face delays due to the growing shortage of trained phlebotomists.”

Aletta autonomously handles every step of the blood draw, while a trained phlebotomist initiates each blood draw procedure and remains present at all times to address any issues that may arise. The device guides the patient in positioning their arm, after which the patient or the supervisor presses a button to begin the blood draw. Aletta then uses near-infrared light and Doppler ultrasound to locate a suitable vein and distinguish it from an artery. If no suitable vein is found, the device will not attempt the blood draw procedure.

Once a vein is identified, Aletta autonomously completes the remaining steps: applying the tourniquet, preparing the skin, inserting and disposing of the needle, changing collection tubes and applying a bandage. The supervising phlebotomist confirms that the collection tubes are filled in the correct order and verifies, upon completion of the procedure, that all collection tubes have been adequately filled.

Aletta was designed with multiple patient safety safeguards in mind. During the ultrasound scanning process, the device continuously applies a disinfectant to the skin. The device is also cleaned by trained professionals between each patient use. If the patient moves excessively during the procedure, the needle automatically disengages and the blood draw stops; additional on-board sensors can pause the procedure and alert the supervisor when other unsafe conditions are detected.

About This Authorization

This authorization advances the FDA's public health pillar goals regarding innovation and global leadership, increasing access to affordable drugs and medical products, and preventing chronic disease and promoting American health, by bringing a transformative technology to patients who increasingly face delays in accessing critical diagnostic services.

The FDA's authorization was based on clinical data demonstrating that, once the device has actually performed the puncture, Aletta's successful blood collection rate is comparable to or better than that of trained human phlebotomists. This performance was demonstrated across a range of patient populations, including patients with varying health conditions, patients who self-report difficult venous access, and people with different skin tones. Device-related adverse events were uncommon and mild in severity.

The FDA granted marketing authorization for Vitestro's Aletta through the De Novo pathway, a regulatory pathway for novel devices of low to moderate risk. Concurrently with this De Novo authorization, the FDA is establishing special controls specifying requirements related to labeling, performance testing and clinical testing. These special controls, in combination with general controls, provide a reasonable assurance of safety and effectiveness when met.

Media Contact

FDA Request for Comment: 202-690-6343
Consumers: 888-INFO-FDA

About the Agency

The FDA is an agency within the U.S. Department of Health and Human Services and protects the public health by ensuring the safety, effectiveness and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of the nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and tobacco products, and for regulating tobacco products.

AIMEILI Regulatory Interpretation and Business Impact

What This Means for Medical Device Companies

Information of this kind, published by FDA CDRH News & Updates, should first be incorporated into a company's regulatory intelligence and post-market surveillance processes rather than read simply as general news. Companies need to determine whether the update concerns a guidance document, a recall or safety communication, a product authorization, digital health, quality systems or post-market regulatory information, and confirm whether it affects existing registration projects or products under development.

Where the content relates to a specific product, testing performance, a risk notice or a regulatory action, companies should further assess whether it affects product classification, the 510(k), De Novo or PMA pathway, technical documentation, labeling and instructions for use, quality system records or post-market reporting obligations. Companies pursuing U.S. market registration should record the source link, publication date, scope of applicability and internal conclusions in their project tracking system.

Documentation to Review

• Basis for product classification and applicable regulatory provisions
• Predicate device selection or substantial equivalence assessment
• Performance testing protocols and reports
• Software and cybersecurity documentation
• Risk management file
• Clinical evidence
• Labeling and instructions for use
• Quality system readiness

Common Risks

• Misjudging the appropriate FDA pathway
• Overlooking changes in guidance documents
• Insufficiently designed performance testing
• Overly broad labeling claims
• Unclear post-market reporting obligations
• Applying documentation prepared for other markets directly to a U.S. registration

AIMEILI Perspective

The FDA's De Novo authorization of the Aletta robotic blood draw device carries several implications for Chinese medical device manufacturers planning to enter the U.S. market. First, the product is a novel device of low to moderate risk authorized through the De Novo pathway, which means that comparable innovative products without a legally marketed predicate can use this regulatory channel to establish a new product classification and marketing pathway. Chinese manufacturers developing robot-assisted blood collection, automated venipuncture or intelligent blood collection workstations should study the special controls FDA has established for this device and assess whether their own products require an early De Novo classification request or whether a suitable predicate can be identified.

Second, from a technical documentation perspective, Aletta's key performance validation focused on blood collection success rate, vein identification accuracy, the ability to distinguish veins from arteries, and adverse event rates. This indicates that FDA's clinical evaluation of automated blood collection devices focuses not only on mechanical performance but also on performance across different patient populations, such as different skin tones, varying venous conditions and differing health statuses. Companies preparing 510(k) or De Novo submissions should plan clinical data collection strategies that align with FDA expectations, particularly validation evidence for imaging technologies (near-infrared light and Doppler ultrasound) and automated puncture algorithms.

Third, labeling and the intended use environment are key compliance points in this authorization. Aletta is restricted to adult outpatient settings, must be supervised by a trained phlebotomist, and one supervisor may oversee no more than three devices at a time. This demonstrates that FDA has clear expectations regarding operator restrictions, environmental requirements and supervision mechanisms for this category of device. When drafting instructions for use, labels and training materials, Chinese companies should clearly specify the intended patient population, operator qualifications, restrictions on the point of use, and safety monitoring requirements, ensuring consistency with the labeling requirements in FDA's special controls.

Fourth, with respect to quality systems and post-market surveillance, Aletta integrates multiple safety mechanisms into its design, including continuous disinfection, cleaning between uses, patient movement detection, automatic needle disengagement and sensor-based pause functions. This indicates that FDA's safety expectations for automated blood collection devices extend beyond product testing to dynamic risk management during actual use. Chinese manufacturers should establish a robust quality management system in accordance with ISO 13485 and incorporate cybersecurity, software updates, adverse event reporting and post-market clinical follow-up into an overall compliance strategy. In addition, companies with blood collection devices already registered in the United States should assess whether this authorization affects current product classifications, substantial equivalence arguments or the competitive landscape, and adjust their registration strategies and labeling claims accordingly.

FAQ

Does an update to a public FDA page necessarily indicate a regulatory change?

No. It does not necessarily indicate a regulatory change; companies must distinguish between news items, guidance documents, database pages, recall information and formal regulatory documents, and should return to the original FDA text and applicable regulations when making material judgments.

A single web update may simply report an authorization, restate existing requirements or revise an informational page. The appropriate approach is to verify the document type, confirm its legal status, and determine whether it creates new obligations or expectations before adjusting internal compliance positions.

What should a company do after seeing an FDA update?

Determine first whether the update affects product classification, the registration pathway, technical documentation or post-market obligations, and only then decide whether the project plan needs to be updated.

A practical sequence is to log the item in the regulatory intelligence tracker, flag affected products and submissions, assess the impact on classification and predicate strategy, review performance testing and clinical evidence needs, and update labeling, quality system records and post-market reporting arrangements as required.

Source and Scope

Source institution: FDA CDRH News & Updates
Original publication date: August 19, 2026
Source link: https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-its-kind-robotic-blood-draw-device

This article is compiled and translated from public information published by FDA CDRH News & Updates. Specific requirements are subject to the latest official publications of the regulatory authority.

Content author: AIMEILI Regulatory Editorial Team
Professional review: AIMEILI Medical Device International Registration Project Team
Source principles: Priority is given to official regulatory authorities, international organizations, standards bodies and public regulatory materials; industry media and project experience are used only as supporting references.
Scope and limitations: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.